Evidence map›Paper›PMID 29905118›Full record

ReviewVisual neuroscience2018

Amblyopia: New molecular/pharmacological and environmental approaches.

Michael P Stryker, Siegrid Löwel

Abstract readReview
In one paragraph

Review in Visual neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Active efficient coding explains the development of binocular vision and its failure in amblyopia.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  19. Silent Synapse-Based Mechanisms of Critical Period Plasticity.Frontiers in cellular neuroscience · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michael P StrykerUCSF Sandler Neurosciences Center,University of California, San Francisco,San Francisco,California.
Siegrid LöwelDepartment of Systems Neuroscience,University of Göttingen,Göttingen,Germany.

Funding

Rapid-Prototyping and Design CoreP30EY002162 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAMBA, DEEPAK ASHOK · 1985 to 2024
$16.8M
DEVELOPMENT &PLASTICITY OF THE VISUAL SYSTEMR01EY002874 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STRYKER, MICHAEL P · 1986 to 2022
$6.4M
NEI NIH HHS P30 EY002162NEI NIH HHS R01 EY002874
6 · The paper itself

Abstract

Emerging technologies are now giving us unprecedented access to manipulate brain circuits, shedding new light on treatments for amblyopia. This research is identifying key circuit elements that control brain plasticity and highlight potential therapeutic targets to promote rewiring in the visual system during and beyond early life. Here, we explore how such recent advancements may guide future pharmacological, genetic, and behavioral approaches to treat amblyopia. We will discuss how animal research, which allows us to probe and tap into the underlying circuit and synaptic mechanisms, should best be used to guide therapeutic strategies. Uncovering cellular and molecular pathways that can be safely targeted to promote recovery may pave the way for effective new amblyopia treatments across the lifespan.

Indexed as

Cognitive Behavioral TherapyMolecular Targeted TherapyPharmaceutical PreparationsAmblyopiaGene-Environment InteractionHumansPharmaceutical PreparationsCritical periodDark exposureE/I balanceEnvironmental enrichmentLight deprivationMonocular deprivationNeuromodulatory systems

Identifiers

PMID29905118
PMCPMC6044412

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.